276 related articles for article (PubMed ID: 31391581)
61. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
62. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
Mus LM; Lambertz I; Claeys S; Kumps C; Van Loocke W; Van Neste C; Umapathy G; Vaapil M; Bartenhagen C; Laureys G; De Wever O; Bexell D; Fischer M; Hallberg B; Schulte J; De Wilde B; Durinck K; Denecker G; De Preter K; Speleman F
Sci Rep; 2020 Jan; 10(1):218. PubMed ID: 31937834
[TBL] [Abstract][Full Text] [Related]
63. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma.
He J; Huang Y; Liu Z; Zhao R; Liu Q; Wei L; Yu X; Li B; Qin Y
Gene; 2017 Sep; 629():29-34. PubMed ID: 28764977
[TBL] [Abstract][Full Text] [Related]
64. Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter.
Kosaka-Suzuki N; Suzuki T; Pugacheva EM; Vostrov AA; Morse HC; Loukinov D; Lobanenkov V
J Biol Chem; 2011 Aug; 286(31):27378-88. PubMed ID: 21659515
[TBL] [Abstract][Full Text] [Related]
65. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
66. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
Bagci O; Tumer S; Olgun N; Altungoz O
Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
[TBL] [Abstract][Full Text] [Related]
67. The structural and functional roles of CTCF in the regulation of cell type-specific and human disease-associated super-enhancers.
Shin HY
Genes Genomics; 2019 Mar; 41(3):257-265. PubMed ID: 30456521
[TBL] [Abstract][Full Text] [Related]
68. Systematic screening of CTCF binding partners identifies that BHLHE40 regulates CTCF genome-wide distribution and long-range chromatin interactions.
Hu G; Dong X; Gong S; Song Y; Hutchins AP; Yao H
Nucleic Acids Res; 2020 Sep; 48(17):9606-9620. PubMed ID: 32885250
[TBL] [Abstract][Full Text] [Related]
69. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
[TBL] [Abstract][Full Text] [Related]
70. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
71. CTCF and CTCFL in cancer.
Debaugny RE; Skok JA
Curr Opin Genet Dev; 2020 Apr; 61():44-52. PubMed ID: 32334335
[TBL] [Abstract][Full Text] [Related]
72. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
73. CTCFL (BORIS) mRNA Expression in a Peripheral Giant Cell Granuloma of the Oral Cavity.
Zambrano-Galván G; Reyes-Romero M; Bologna-Molina R; Almeda-Ojeda OE; Lemus-Rojero O
Case Rep Dent; 2014; 2014():792615. PubMed ID: 25114808
[TBL] [Abstract][Full Text] [Related]
74. BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells.
Renaud S; Loukinov D; Alberti L; Vostrov A; Kwon YW; Bosman FT; Lobanenkov V; Benhattar J
Nucleic Acids Res; 2011 Feb; 39(3):862-73. PubMed ID: 20876690
[TBL] [Abstract][Full Text] [Related]
75. The function of brother of the regulator of imprinted sites in cancer development.
Zhou S; Li L; Zhang M; Qin Y; Li B
Cancer Gene Ther; 2023 Feb; 30(2):236-244. PubMed ID: 36376421
[TBL] [Abstract][Full Text] [Related]
76. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
77. ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.
Somasundaram DB; Aravindan S; Gupta N; Yu Z; Baker A; Aravindan N
World J Pediatr; 2022 Apr; 18(4):285-293. PubMed ID: 35132576
[No Abstract] [Full Text] [Related]
78. Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface.
Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM
Cancer Res; 2019 Nov; 79(21):5652-5667. PubMed ID: 31501192
[TBL] [Abstract][Full Text] [Related]
79. Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer.
Zhang Y; Fang M; Song Y; Ren J; Fang J; Wang X
Sci Rep; 2017 Jan; 7():40786. PubMed ID: 28098226
[TBL] [Abstract][Full Text] [Related]
80. Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies.
Voutsadakis IA
High Throughput; 2018 Oct; 7(4):. PubMed ID: 30275357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
